Peer review reports
From: Remimazolam protects the liver from ischemia-reperfusion injury by inhibiting the MAPK/ERK pathway
| Original Submission | ||
|---|---|---|
| 25 Jan 2024 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 26 Feb 2024 | Reviewed | Reviewer Report - Jianhua Li |
| 10 Mar 2024 | Reviewed | Reviewer Report |
| 7 Apr 2024 | Author responded | Author comments - Zhiqin Zeng |
| Resubmission - Version 4 | ||
| 7 Apr 2024 | Submitted | Manuscript version 4 |
| 26 Apr 2024 | Author responded | Author comments - Zhiqin Zeng |
| Resubmission - Version 5 | ||
| 26 Apr 2024 | Submitted | Manuscript version 5 |
| 1 May 2024 | Reviewed | Reviewer Report |
| 19 Jun 2024 | Author responded | Author comments - Zhiqin Zeng |
| Resubmission - Version 6 | ||
| 19 Jun 2024 | Submitted | Manuscript version 6 |
| Publishing | ||
| 15 Jul 2024 | Editorially accepted | |
| 25 Jul 2024 | Article published | 10.1186/s12871-024-02641-3 |